Despite reasonably solid gains across most sectors, the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) edged higher by just over 0.1% to 5,561 points today.

There were four shares in particular that did a lot of the heavy lifting, each posting incredibly strong gains for their respective shareholders. Here’s why they soared:

Ardent Leisure Group (ASX: AAD) shares surged 14% to $2.85 following the release of its full year results which revealed a 32% jump in net profit after tax to $42 million. As this report states, whilst the strong profit growth is fantastic and will no doubt have excited many investors, it is likely to be the incredible potential of the company’s Main Event family entertainment centres in the United States which is the real reason for the buying frenzy.

Ardent Leisure’s share price has now rocketed almost 25% in the last five trading days.

Altium Limited (ASX: ALU) shares have jumped almost 13% to $8.25 after reporting a strong full year result. The printed circuit board software provider reported revenue growth of 16.7% to US$93.6 million and normalised earnings-per-share grew a massive 43.5% to 17.9 US cents. With the company turning its attention to achieving market leadership and $200 million revenue by 2020, now could be a great time to look at a long-term investment in my opinion.

Altium shares have risen 76% so far in 2016.

iSentia Group Ltd (ASX: ISD) shares have bolted higher by almost 17% to $3.63. Today’s increase came thanks to the tech company reporting solid full year results which revealed a 23.6% rise in net profit after tax to $24.3 million. Driving the strong result was a 51% increase in revenue from its Asia/Rest of the World division. Elsewhere a better-than-expected performance from the recently acquired King Content business was a further boost to revenue.

iSentia’s shares are still down 26% year to date despite today’s gains.

Sirtex Medical Limited (ASX: SRX) shares jumped a massive 12% to $34.80 after the cancer treatment specialist reported net profit of $53.6 million on revenues of $232.5 million for FY 2016. This represented impressive year on year growth of 33% and 32% respectively. Today’s strong result was thanks largely to strong growth in dose sales in its core US market which helped take overall dose sales higher by 16.4% year on year.

Sirtex Medical’s share price is still down around 13% in 2016.

If you've missed out on gains today don't worry. If you have just $10k ready to invest I would highly recommend taking a look at how this man turned that $10k investment into $8 million. Incredible!

How 1 Man Turned $10K Into Over $8 Million

Discover how one man turned a modest $10,600 investment into an $8,016,867 fortune. Learn more about this man and how you can start down the path toward financial independence. Simply click here to learn more.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia owns shares of Altium. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.